Medtronic Announces Quarterly Cash Dividend of $0.71 Per Share for Q2 FY 2026
ByAinvest
Thursday, Aug 14, 2025 4:17 pm ET1min read
MDT--
Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company that has consistently increased its annual dividend payment for the past 48 consecutive years. This dividend increase underscores the company's commitment to rewarding shareholders and its strong financial health.
Despite recent challenges, including a 33% decline in stock value since mid-2021, Medtronic remains committed to improving its overall profitability and innovation. The company plans to spin off its diabetes business next year, which is expected to be accretive to earnings and free up capital for research and development or potential acquisitions.
Investors should note that Medtronic's business and stock performance may not improve overnight. The company is working on new product launches and addressing the challenges of regulatory approval and product development. However, the dividend yield currently stands at around 3.1%, historically high for the stock and well above the S&P 500 index's 1.2% yield.
References:
[1] https://www.aol.com/3-things-know-buy-medtronic-100000838.html
[2] https://www.prnewswire.com/news-releases/medtronic-announces-cash-dividend-for-second-quarter-of-fiscal-year-2026-302530564.html
Medtronic has announced a cash dividend of $0.71 per ordinary share for the second quarter of fiscal year 2026. This is consistent with the dividend increase announced in May 2025. The dividend is payable on October 17, 2025, to shareholders of record at the close of business on September 26, 2025.
Medtronic plc (NYSE: MDT) has announced a cash dividend of $0.71 per ordinary share for the second quarter of fiscal year 2026. This dividend is consistent with the dividend increase announced in May 2025 and is payable on October 17, 2025, to shareholders of record at the close of business on September 26, 2025.Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company that has consistently increased its annual dividend payment for the past 48 consecutive years. This dividend increase underscores the company's commitment to rewarding shareholders and its strong financial health.
Despite recent challenges, including a 33% decline in stock value since mid-2021, Medtronic remains committed to improving its overall profitability and innovation. The company plans to spin off its diabetes business next year, which is expected to be accretive to earnings and free up capital for research and development or potential acquisitions.
Investors should note that Medtronic's business and stock performance may not improve overnight. The company is working on new product launches and addressing the challenges of regulatory approval and product development. However, the dividend yield currently stands at around 3.1%, historically high for the stock and well above the S&P 500 index's 1.2% yield.
References:
[1] https://www.aol.com/3-things-know-buy-medtronic-100000838.html
[2] https://www.prnewswire.com/news-releases/medtronic-announces-cash-dividend-for-second-quarter-of-fiscal-year-2026-302530564.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet